Stock Traders Purchase Large Volume of Boston Scientific Call Options (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading on Monday. Stock investors acquired 212,430 call options on the stock. This represents an increase of 527% compared to the typical volume of 33,884 call options.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BSX. Brighton Jones LLC boosted its stake in Boston Scientific by 45.8% in the 3rd quarter. Brighton Jones LLC now owns 80,361 shares of the medical equipment provider’s stock worth $3,508,000 after buying an additional 25,252 shares during the last quarter. Candriam S.C.A. increased its stake in shares of Boston Scientific by 17.1% during the 3rd quarter. Candriam S.C.A. now owns 430,284 shares of the medical equipment provider’s stock valued at $18,851,000 after acquiring an additional 62,799 shares during the last quarter. Ethic Inc. increased its stake in shares of Boston Scientific by 11.1% during the 3rd quarter. Ethic Inc. now owns 232,231 shares of the medical equipment provider’s stock valued at $10,137,000 after acquiring an additional 23,294 shares during the last quarter. 180 Wealth Advisors LLC increased its stake in shares of Boston Scientific by 37.4% during the 3rd quarter. 180 Wealth Advisors LLC now owns 12,678 shares of the medical equipment provider’s stock valued at $553,000 after acquiring an additional 3,453 shares during the last quarter. Finally, StoneX Group Inc. lifted its holdings in shares of Boston Scientific by 35.0% during the 3rd quarter. StoneX Group Inc. now owns 9,636 shares of the medical equipment provider’s stock worth $421,000 after acquiring an additional 2,499 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on BSX. Canaccord Genuity Group dropped their price target on Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Wells Fargo & Company decreased their price objective on Boston Scientific from $48.00 to $45.00 and set an “equal weight” rating for the company in a report on Thursday, October 29th. BTIG Research lowered their price objective on shares of Boston Scientific from $56.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, October 29th. Needham & Company LLC dropped their target price on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. Finally, TD Cowen cut shares of Boston Scientific from a “buy” rating to a “hold” rating and dropped their target price for the stock from $56.00 to $46.00 in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Trading Down 1.7%

Shares of NYSE:BSX opened at $43.58 on Wednesday. The business’s 50-day moving average is $44.55 and its 200 day moving average is $56.38. Boston Scientific has a 1 year low of $39.57 and a 1 year high of $105.65. The firm has a market capitalization of $63.15 billion, a P/E ratio of 18.47, a P/E/G ratio of 1.29 and a beta of 0.60. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. Boston Scientific’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. On average, research analysts predict that Boston Scientific will post 3.17 earnings per share for the current fiscal year.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
• Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
• Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
• Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.